CNBC's Meg Tirrell reports the latest earnings results for AstraZeneca, Bristol-Myers and Celgene. » Read More
CNBC's Meg Tirrell reports on Valeant possibly not living up to its promise to offer discounts on some drugs.
David Amsellem of Piper Jaffray discusses a report that hospitals are still waiting on Valeant's promised drug discounts.
The study said when people took acetaminophen, Tylenol's main ingredient, they were less likely to empathize with people experiencing pain. The USAToday reports.
The company's COO is departing as its flagship laboratory operations are threatened with sanctions, The New York Times reports.
Hedge fund manager Bill Ackman is parting company with the man who introduced him to his bad investment in Valeant Pharmaceuticals.
A judge has unsealed records from a Kentucky lawsuit against the maker of the prescription painkiller OxyContin.
There is also strong opposition to speeding up the federal drug approval process, a new poll finds.
These professors point out some "glaring errors" in the attack on Bernie Sanders' single-payer health plan.
Allergan reported a 48 percent rise in quarterly revenue, led by a strong performance by its branded drugs business.
Valeant said on Monday it expects to file its first-quarter report with the regulators on or before June 10, ahead of the July 31 deadline.
A new home conception kit offers health insurers a less expensive alternative to pricey fertility treatments.
If you can't charge "hundreds of thousands" of dollars a year for drugs, will there be drugs for orphan diseases?
Merck reported better-than-expected profit in the first quarter, driven by higher sales of its diabetes drug Januvia and heart drug Zetia.
Obamacare is under threat from politicians. Here's how the affordable care act can work for employers, says industry veteran Denny Weinberg.
Pfizer has approached U.S. cancer drug maker Medivation to express interest in an acquisition, raising the possibility of a bid.
CNBC's Meg Tirrell reports prosecutors may file new charges against Martin Shkreli. His next court hearing is set for June 6th.
Martin Shkreli made an appearance at the U.S. Federal Court in Brooklyn for a hearing related to securities fraud charges.
Pfizer reported a 19.7 percent rise in quarterly revenue, boosted by sales of its new treatments for cancer and its Hospira acquisition.
A drug company previously headed by Martin Shkreli was sued for allegedly breaching a contract that let it sell Daraprim. USA Today reports.
GlaxoSmithKline CEO Andrew Whitty thinks his company's success has been a product of being patient and investing in innovation.
Get the best of CNBC in your inbox